
Ally Bridge Group, a Hong Kong-based healthcare-focused private equity firm, has proposed a HK$2.34 billion (US$301 million) privatization deal to take Hong Kong-listed Shangdong Luoxin Pharmaceutical Group Stock Co., Ltd. private.

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!